RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
Contineum Therapeutics Inc CTNM
$15.49
▼ -1.65%
($-0.26)
📅 Earnings This Week
Open
$15.75
Prev Close
$15.75
Day Range
$14.13 – $16.08
52W Range
$5.07 – $16.91
Market Cap
$579.11M
Beta
0.40
EPS (TTM)
$-1.95
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-04-05 |
| Shares Out. | 37,390,000 |
| Website | contineum-tx.com/ ↗ |
| Phone | 18583335280 |
| Employees | 51 |
| Net Income | -$14.5M |
| Free Cash Flow | -$57.7M |
| Total Assets | $261.3M |
| Total Liabilities | $11.3M |
| Equity | $250.0M |
About Contineum Therapeutics Inc
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics Inc is a publicly traded company under the ticker symbol CTNM on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)